Berberine and Semaglutide
Supplement–drug interaction evidence from the TruthStack database.
| Severity | MODERATE |
|---|---|
| Evidence Tier | Moderate |
| Interaction Type | PHARMACODYNAMIC RISK |
| Mechanism | PHARMACODYNAMIC |
| Last Reviewed | 2026-02-15 |
Summary
Both berberine and semaglutide lower blood glucose through different mechanisms (AMPK activation vs GLP-1 receptor agonism). Combining them may increase hypoglycemia risk. Monitor blood glucose closely and discuss with prescriber.
CYP Enzyme Pathway Overlap
Berberine and Semaglutide share activity on the following CYP enzymes:
| Enzyme | Berberine | Semaglutide |
|---|---|---|
| CYP3A4 | INHIBITOR (STRONG) | SUBSTRATE (WEAK) |
Shared Pharmacodynamic Endpoints
Both compounds influence the same physiological endpoints in the same direction:
| Endpoint | Direction | Berberine | Semaglutide |
|---|---|---|---|
| BLOOD GLUCOSE | DECREASE | STRONG | STRONG |
Cumulative effect on shared endpoints may exceed individual compound profiles. This is relevant to discussion with a prescribing clinician.
API Reference
GET https://api.truthstack.co/v1/check?c1=berberine&c2=semaglutide
Open, unauthenticated. Returns JSON. Developer documentation
Related Interactions
What this page is and is not. TruthStack is an informational reference database that describes published pharmacological findings. It does not provide medical advice, diagnosis, or treatment recommendations. The information on this page reflects flags in our database and should not replace consultation with a qualified healthcare provider. Always discuss supplement-drug combinations with your prescriber or pharmacist.